PM14, IRINOTECAN clinical trials

Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM14 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors

This study is testing a new drug called PM14 alongside an existing cancer medicine, Irinotecan, for people with advanced solid cancers. It aims to find the safest and most effective dose of PM14 and see how well the combination shrinks tumours and how the body handles the new medicine.